New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
07:28 EDTBCRXBioCryst price target raised to $24 from $21 at H.C. Wainwright
H.C. Wainwright raised its price target for BioCryst shares to $24 saying two overhangs have been removed with the positive Phase 2a data for oral kallikrein inhibitor 4161 and the recent equity financing. The firm reiterates a Buy rating on the stock.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
10:00 EDTBCRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:26 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:45 EDTBCRXBioCryst upgraded to Buy on BCX7353 potential at BofA/Merrill
As previously reported, BofA/Merrill upgraded BioCryst to Buy from Neutral and increased its price target to $19 from $12. The firm raised the probability of BCX7353 approval to 40% from 25% given validation of the plasma kallikrein target by both 4161 and competitor product and now assign a $13/share value versus near zero previously. BofA/Merrill is now assigning a modest negative value for '4161 versus approximately $7/share previously.
06:00 EDTBCRXBioCryst upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use